ME/CFS Science @mecfsscience.org · 10d 6) The main result is shown in the figure below. Temelimab had no effect on fatigue, and the same null results were seen for the secondary outcomes, including several cognitive tests and biomarkers.
6 likes 1 replies
?
Replies
7) The trial was sponsored by the Swiss biopharma company GeNeuro, which makes the drug. A couple of years ago, a randomized trial of Temelimab in multiple sclerosis also failed on its primary outcome. pubmed.ncbi.nlm.nih....